Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders

Acta Haematol. 2009;122(1):46-9. doi: 10.1159/000243721. Epub 2009 Oct 7.

Abstract

Background: Myeloproliferative neoplasms likely involve both myeloid and lymphoid lineages. Nevertheless, the coincidence of chronic myeloproliferative and lymphoproliferative diseases in the same patient is a rare phenomenon.

Methods: We report a case of a patient having essential thrombocythemia (ET) and B-chronic lymphocytic leukemia (B-CLL). In this patient and in 2 relatives with lymphoproliferative disorders, we searched for JAK2(V617F) mutation in lymphocytes.

Results: In the patient with ET and B-CLL, we identified homozygous JAK2(V617F) mutation in the granulocytic compartment. Both relatives were heterozygous for JAK2(V617F) mutation, whereas no mutation signal could be detected in the lymphoid compartment of all 3 patients.

Conclusion: Our results seem to confirm that CLL cases are negative for JAK2(V617F) mutation in B- and T-lymphocyte populations.Presence of JAK2(V617F) mutation in subjects without myeloproliferative diseases could indicate an increased risk of a future myeloproliferative neoplasm development.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • B-Lymphocytes / enzymology
  • Female
  • Granulocytes / enzymology
  • Humans
  • Janus Kinase 2 / genetics*
  • Leukemia, Lymphocytic, Chronic, B-Cell / complications*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Lymphoproliferative Disorders / genetics
  • Male
  • Middle Aged
  • T-Lymphocytes / enzymology
  • Thrombocythemia, Essential / complications*
  • Thrombocythemia, Essential / genetics*

Substances

  • Janus Kinase 2